Please assess the completion status of the following clinical trial:

Trial Title: MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the current ESC Guidelines or ACCF/AHA/HRS Class I or Class IIa indications for CRT implant (including upgrades from single or dual chamber ICDs)~* Must be willing and able to comply with study requirements~* Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form~Exclusion Criteria:~* Already had a CRT device implanted~* Myocardial Infarction, unstable angina within 40 days prior the enrollment~* Recent cardiac revascularization (PTCA, Stent or CABG) in the 4 weeks prior to enrollment or planned for the 3 months following~* Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) in the 3 months prior the enrollment~* Primary valvular disease~* Atrial Fibrillation:~  * Persistent AF at the time of enrollment~ * Permanent AF not treated with AV node ablation within 2 weeks from the CRT implant~ * History or incidence of Paroxysmal or Persistent AF within 30 days prior the enrollment~* Unable to comply with the follow up schedule~* Less than 18 years of age~* Pregnant or are planning to become pregnant during the duration of the investigation~* Classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 12 months~* Undergone a cardiac transplantation~* Life expectancy \< 12 months~* Currently participating in any other clinical investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPP ON (Type: EXPERIMENTAL): MPP ON: feature is enabled
- MPP OFF (Type: NO_INTERVENTION): MPP OFF: feature not enabled

Based on this trial design, predict the completion outcome and termination type (if applicable).